Prothena (PRTA)
(Delayed Data from NSDQ)
$6.81 USD
-0.06 (-0.87%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $6.80 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRTA 6.81 -0.06(-0.87%)
Will PRTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRTA
PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline
PRTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
Other News for PRTA
Prothena (PRTA) Set to Report Q2 Earnings Amid Workforce Cuts
Prothena Q2 2025 Earnings Preview
A Glimpse of Prothena Corp's Earnings Potential
Prothena to Report Second Quarter 2025 Financial Results on August 4 | PRTA Stock News
Cantor Fitzgerald Keeps Their Hold Rating on Prothena (PRTA)